Top Story

NovaBay reports lower net loss in 2014

March 31, 2015

NovaBay Pharmaceuticals reported a 2014 net loss of $15.2 million, or $0.31 per share, compared with $16 million, or $0.42 per share, in 2013, according to a press release.

The lower net loss in 2014 was attributed to decreased spending on research and development activities. Sales revenue was $684,000 in 2014 compared with $223,000 in 2013.

Andrew Schachat In the JournalsPerspective

Switch to Eylea reduces fluid, improves visual acuity in eyes with wet AMD

March 31, 2015
Fluid was reduced and visual acuity was improved in eyes with neovascular age-related macular degeneration that received Eylea after multiple intravitreal injections of…
Evolution of the Eye: What changes might be induced in the eye with higher use of near vision?

Evolution of the Eye: What changes might be induced in the eye with higher use of near vision?

March 31, 2015
The third question included in my survey, which was sent by Ocular Surgery News Europe Edition to ophthalmology leaders worldwide, focused on changes that the intense…
thumbnail for video 4143065091001 Meeting News CoverageVideo

VIDEO: The role of posterior corneal surface in astigmatism correction during cataract surgery

March 31, 2015
John A. Hovanesian, MD, FACS, discusses a variety of techniques available to correct astigmatism.
Breaking News

IMPACT: No difference in number of injections with or without squalamine lactate for wet AMD

March 30, 2015
No meaningful difference was found in mean number of injections of squalamine lactate ophthalmic solution combined with Lucentis compared with Lucentis monotherapy for…
More News Headlines »
Practical Retina

Comparing Aflibercept, Bevacizumab, and Ranibizumab for DME: Analysis of DRCR Protocol T

Ophthalmic Surgery, Lasers and Imaging Retina
Online Advanced Release, March 5, 2015
More »
CME
Ocular Surface Disease in the Surgical Setting

Ocular Surface Disease in the Surgical Setting: Recognition and Treatment of an Increasing Dilemma

This activity is supported by an educational grant from Allergan, Inc.

Dry eye disease (DED) is becoming an increasing burden as the population ages or undergoes treatments, procedures, or…
More »
Meeting News Coverage Video
thumbnail for video 4138719116001

VIDEO: Emerging therapies for diabetic macular edema

March 30, 2015
Peter K. Kaiser, MD, highlights emerging new classes of treatment for retinal eye diseases and diabetic macular edema…
More »
morganatic-roan
morganatic-roan